Trial Profile

Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tenofovir disoproxil fumarate (Primary) ; Hepatitis B immune globulin; Hepatitis B vaccine
Indications Hepatitis B
Focus Therapeutic Use
Sponsors New Discovery

08 Nov 2022 Results of safety NCT03476083 and other studies ,presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
10 Dec 2019 Planned End Date changed from 1 May 2022 to 1 May 2024.
10 Dec 2019 Planned primary completion date changed from 1 May 2020 to 1 May 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com